Gastrointestinal involvement represents one of the most debilitating manifestations of systemic sclerosis, prompting widespread acid-suppressive therapy. For decades, clinicians have prescribed proton pump inhibitors scleroderma regimens not only to relieve painful reflux esophagitis but also to prevent pulmonary microaspiration. However, recent evidence from large international registries presents a nuanced picture regarding their actual disease-modifying benefits. Therefore, rheumatologists and gastroenterologists must carefully re-examine the therapeutic role of these routine medications.

The Rationale Behind Proton Pump Inhibitors Scleroderma Regimens

Esophageal dysmotility affects nearly ninety percent of patients diagnosed with systemic sclerosis. Atrophy of the smooth muscle and neurovascular impairment significantly weaken lower esophageal sphincter pressure. Consequently, severe gastroesophageal reflux emerges early during the clinical course. In addition, delayed gastric emptying worsens both acidic and non-acidic regurgitation. Pulmonologists frequently hypothesize that chronic microaspiration provokes repetitive alveolar injury, driving the development of interstitial lung disease. Because occult aspiration damages delicate lung architecture, specialists routinely initiate empirical acid suppression. Clinicians therefore consider proton pump inhibitors a foundational supportive treatment. Furthermore, many physicians prescribe escalated doses even when patients report minimal esophageal discomfort. Healthcare professionals hope that aggressive acid suppression preserves functional lung capacity over time. Nevertheless, objective evidence supporting this protective pulmonary hypothesis has remained largely observational and conflicting. Most prior studies lacked adequate sample sizes or robust methods to control for indication bias. Consequently, practice patterns vary widely across international centers without standardized treatment protocols.

Real-World Evidence from the EUSTAR Cohort

To address these critical uncertainties, investigators evaluated data from the extensive European Scleroderma Trials and Research database. This comprehensive multicenter registry followed 10,660 patients over an average duration of nearly six years. Notably, 8,637 individuals, representing eighty-one percent of the total population, received proton pump inhibitor therapy. Patients receiving acid suppression consistently displayed a significantly more severe multisystem phenotype. Specifically, this cohort demonstrated extensive cutaneous involvement, frequent digital ulcers, and severe baseline pulmonary impairment. In addition, gastrointestinal symptoms were far more prevalent among these treated individuals. To overcome profound confounding by indication, the authors applied inverse probability of treatment weighting with propensity scores. The research team evaluated all-cause mortality using weighted, time-varying survival models. Concurrently, they monitored pulmonary function using serial forced vital capacity and diffusing capacity measurements. Additionally, the investigators utilized restricted mean survival time to calculate absolute differences between groups. Sensitivity analyses included a six-month lag period to avoid reverse causation. Ultimately, this rigorous observational design yielded robust real-world insights into long-term clinical trajectories.

Interpreting All-Cause Mortality and Confounding by Indication

After multivariate adjustment, the analysis revealed that proton pump inhibitor exposure correlated with increased all-cause mortality. The weighted model generated a hazard ratio of 1.88, reflecting a notable statistical divergence. However, when evaluating restricted mean survival time at five years, the absolute survival difference was minimal. This crucial observation indicates that the elevated hazard ratio does not produce substantial immediate survival loss. Furthermore, the registry could not collect cause-specific mortality details, preventing direct causal attribution. Experienced rheumatologists understand that severe gastrointestinal dysmotility reflects extensive visceral fibrosis and systemic vasculopathy. Patients who require intensive acid suppression typically suffer from advanced, aggressive disease. Therefore, this apparent mortality association likely mirrors underlying multisystem severity rather than direct drug toxicity. In addition, severe reflux frequently causes malnutrition, aspiration pneumonia, and frailty. Consequently, doctors should not view acid suppression as a direct driver of patient mortality. Instead, clinicians must recognize severe gastroesophageal reflux as a reliable clinical marker of high-risk systemic disease.

Assessing Interstitial Lung Disease Progression and Pulmonary Function

A central clinical rationale for acid suppression focuses on preserving respiratory function. Proponents suggest that lowering gastric acidity prevents aspiration-induced alveolar damage and slows pulmonary fibrosis. Surprisingly, the EUSTAR study revealed that proton pump inhibitors did not prevent forced vital capacity decline. Specifically, treated patients experienced similar rates of five percent and ten percent capacity loss compared to untreated peers. However, the researchers observed a modest attenuation in diffusing capacity for carbon monoxide deterioration. Nevertheless, the absolute progression-free survival difference between groups remained very small over long-term follow-up. In addition, standard proton pump inhibitors reduce gastric acid secretion but cannot prevent mechanical fluid reflux. Regurgitated volume containing bile acids and digestive enzymes continues to reach the airway mucosa despite acid suppression. Thus, pharmacological acid inhibition fails to eliminate non-acid aspiration injury in vulnerable lungs. Accordingly, clinicians cannot rely on acid suppression alone to protect against progressive fibrotic lung disease. Specialist teams must instead prioritize proven antifibrotic and immunomodulatory agents to preserve vital lung volumes.

Clinical Implications and Optimizing Patient Management

These registry findings offer practical guidance for optimizing care in systemic sclerosis. Because proton pump inhibitors provide minimal pulmonary protection, clinicians should not prescribe them solely to prevent lung fibrosis. Instead, physicians should direct acid suppression toward relieving symptomatic heartburn and healing erosive reflux esophagitis. Furthermore, doctors must emphasize mechanical and lifestyle antireflux measures alongside pharmacotherapy. Recommended strategies include elevating the head of the bed, eating smaller meals, and avoiding late-night food intake. In addition, clinicians should regularly re-evaluate medication regimens to determine the lowest effective dose needed for symptom control. When patients exhibit progressive interstitial lung disease, specialists must promptly initiate targeted therapies like nintedanib or tocilizumab. Similarly, healthcare providers should monitor long-term safety considerations, such as bone density loss, enteric infections, and hypomagnesemia. Periodic clinical reviews ensure that patients receive appropriate monitoring without unnecessary polypharmacy. Ultimately, a balanced, individualized approach provides optimal gastrointestinal symptom relief while properly managing life-threatening pulmonary complications.

Why did PPI use correlate with higher all-cause mortality in the EUSTAR study?

The correlation between proton pump inhibitor exposure and higher mortality largely reflects confounding by indication rather than direct drug toxicity. In systemic sclerosis, severe gastrointestinal dysmotility mirrors widespread microvascular damage and multi-organ involvement. Consequently, patients requiring continuous acid suppression inherently possess a more severe disease phenotype. Because the registry lacked cause-specific death data, this elevated hazard ratio serves primarily as a surrogate marker of advanced systemic illness.

Do proton pump inhibitors prevent progressive lung function decline in scleroderma?

Proton pump inhibitors do not significantly prevent clinically meaningful declines in forced vital capacity. Although treated patients demonstrated a modest attenuation of diffusing capacity decline, absolute progression-free differences remained minimal. Standard acid suppressants neutralize gastric acid effectively, but they do not eliminate non-acidic microaspiration or mechanical regurgitation into the lungs. Therefore, clinicians must rely on approved antifibrotic medications and immunosuppressive therapies rather than acid-suppressing drugs to halt pulmonary fibrosis progression.

Should clinicians discontinue proton pump inhibitors in patients with systemic sclerosis?

Clinicians should definitely not discontinue proton pump inhibitors if patients have symptomatic reflux or proven esophagitis. Uncontrolled gastroesophageal reflux causes severe erosive disease, esophageal strictures, and painful mucosal ulcerations. However, healthcare providers should avoid initiating high-dose regimens solely for pulmonary protection. Instead, treatment decisions must target gastrointestinal symptoms directly while using the lowest effective dosage. Additionally, clinicians should combine medication therapy with postural interventions to minimize reflux complications safely.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to replace consultation with a qualified healthcare professional. Healthcare professionals should apply their clinical judgment to determine the most appropriate care for individual patients. Refer to the latest local and national guidelines for clinical practice.

References

Bonomi F et al. Proton pump inhibitor use and long-term outcomes in systemic sclerosis: a real-life analysis from the EUSTAR database. Rheumatology (Oxford). 2026 Sep 18. doi: undefined. PMID: 42760267.

Hughes M, Allanore Y, Baron M, et al. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. Lancet Rheumatol. 2022;4(11):e795-e803.

Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219-227.